Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.3.1053

Activating Transcription Factor 1 is a Prognostic Marker of Colorectal Cancer  

Huang, Guo-Liang (Sino-American Cancer Research Institute, Guangdong Medical College)
Guo, Hong-Qiang (The Affiliated Cancer Hospital of Zhengzhou University)
Yang, Feng (Department of Pharmacy and Life Science, University of South China)
Liu, Ou-Fei (The Affiliated Cancer Hospital of Zhengzhou University)
Li, Bin-Bin (Sino-American Cancer Research Institute, Guangdong Medical College)
Liu, Xing-Yan (Sino-American Cancer Research Institute, Guangdong Medical College)
Lu, Yan (Sino-American Cancer Research Institute, Guangdong Medical College)
He, Zhi-Wei (Sino-American Cancer Research Institute, Guangdong Medical College)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.3, 2012 , pp. 1053-1057 More about this Journal
Abstract
Objective: Identifying cancer-related genes or proteins is critical in preventing and controlling colorectal cancer (CRC). This study was to investigate the clinicopathological and prognostic value of activating transcription factor 1 (ATF1) in CRC. Methods: Protein expression of ATF1 was detected using immunohistochemistry in 66 CRC tissues. Clinicopathological association of ATF1 in CRC was analyzed with chi-square test or Fisher's exact test. The prognostic value of ATF1 in CRC is estimated using the Kaplan-Meier analysis and Cox regression models. Results: The ATF1 protein expression was significantly lower in tumor tissues than corresponding normal tissues (51.5% and 71.1%, respectively, P = 0.038). No correlation was found between ATF1 expression and the investigated clinicopathological parameters, including gender, age, depth of invasion, lymph node status, metastasis, pathological stage, vascular tumoral emboli, peritumoral deposits, chemotherapy and original tumor site (all with P > 0.05). Patients with higher ATF1 expression levels have a significantly higher survival rate than that with lower expression (P = 0.026 for overall survival, P = 0.008 for progress free survival). Multivariate Cox regression model revealed that ATF1 expression and depth of invasion were the predictors of the overall survival (P = 0.008 and P = 0.028) and progress free survival (P = 0.002 and P = 0.005) in CRC. Conclusions: Higher ATF1 expression is a predictor of a favorable outcome for the overall survival and progress free survival in CRC.
Keywords
ATF1; coloretal cancer; prognosis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Bosilevac JM, Olsen RJ, Bridge JA, Hinrichs SH (1999). Tumor cell viability in clear cell sarcoma requires DNA binding activity of the EWS/ATF1 fusion protein. J Biol Chem, 274, 34811-8.   DOI
2 Eferl R, Wagner EF (2003). AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer, 3, 859-68.   DOI
3 Feuerstein ND, Huang S, Hinrichs H, et al (1995). Regulation of cAMP-responsive enhancer binding proteins during cell cycle progression in T lymphocytes stimulated by IL-2. J Immunol, 154, 68-79.
4 Ghoneim C, Soula-Rothhut M, Blanchevoye C, et al (2007). Activating transcription factor-1-mediated hepatocyte growth factor-induced down-regulation of thrombospondin-1 expression leads to thyroid cancer cell invasion. J Biol Chem, 282, 15490-7.   DOI
5 Gunderson LL, Jessup JM, Sargent DJ, et al (2010). Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol, 28, 264-71.   DOI
6 Hai T, Hartman MG (2001). The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis. Gene, 273, 1-11.   DOI
7 Hsueh YP, Lai MZ (1995). Overexpression of activation transcriptional factor 1 in lymphomas and in activated lymphocytes. J Immunol, 154, 5675-83.
8 Huang D, Shipman-Appasamy PM, Orten DJ, et al (1994). Promoter activity of the proliferating-cell nuclear antigen gene is associated with inducible CRE-binding proteins in interleukin 2-stimulated T lymphocytes. Mol Cell Biol, 14, 4233-43.   DOI
9 Jean D, Tellez C, Huang S, et al (2000). Inhibition of tumor growth and metastasis of human melanoma by intracellular anti-ATF-1 single chain Fv fragment. Oncogene, 19, 2721- 30.   DOI
10 Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.   DOI
11 Kelly D, Kim SJ, Rizzino A (1998). Transcriptional activation of the type II transforming growth factor-beta receptor gene upon differentiation of embryonal carcinoma cells. J Biol Chem, 273, 21115-24.   DOI
12 Kelly D, Scholtz B, Orten DJ, et al (1995). Regulation of the transforming growth factor-beta 2 gene promoter in embryonal carcinoma cells and their differentiated cells: differential utilization of transcription factors. Mol Reprod Dev, 40, 135-45.   DOI
13 Lopez-Bergam P, Lau E, Ronai Z (2010). Emerging roles of ATF2 and the dynamic AP1 network in cancer. Nat Rev Cancer, 10, 65-76.   DOI
14 Maekawa T, Sano Y, Shinagawa T, et al (2008). ATF-2 controls transcription of Maspin and GADD45 alpha genes independently from p53 to suppress mammary tumors. Oncogene, 27, 1045-54.   DOI
15 Okuyama Y, Sowa Y, Fujita T, et al (1996). ATF site of human RB gene promoter is a responsive element of myogenic differentiation. FEBS Lett, 397, 219-24.   DOI
16 Papassava P, Gorgoulis VG, Papaevangeliou D, et al (2004). Overexpression of activating transcription factor-2 is required for tumor growth and progression in mouse skin tumors. Cancer Res, 64, 8573-84.   DOI
17 Ronai Z, Yang YM, Fuchs SY, et al (1998). ATF2 confers radiation resistance to human melanoma cells. Oncogene, 16, 523-31.   DOI
18 Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29.   DOI   ScienceOn
19 Bhoumik A, Fichtman B, Derossi C, et al (2008). Suppressor role of activating transcription factor 2 (ATF2) in skin cancer. Proc Natl Acad Sci U S A, 105, 1674-9.   DOI
20 Belkhiri A, Dar AA, Zaika A, et al (2008). t-Darpp promotes cancer cell survival by up-regulation of Bcl2 through Aktdependent mechanism. Cancer Res, 68, 395-403.   DOI
21 Bhoumik A, Jones N, Ronai Z (2004). Transcriptional switch by activating transcription factor 2-derived peptide sensitizes melanoma cells to apoptosis and inhibits their tumorigenicity. Proc Natl Acad Sci U S A, 101, 4222-7.   DOI
22 Zucman J, Delattre O, Desmaze C, et al (1993). EWS and ATF-1 gene fusion induced by t (12;22) translocation in malignant melanoma of soft parts. Nat Genet, 4, 341-5.   DOI   ScienceOn
23 Su B, Tang HL, Deng M, et al (2011). Stage-associated dynamic activity profile of transcription factors in nasopharyngeal carcinoma progression based on protein/DNA array analysis. Omics, 15, 49-60.   DOI
24 Zheng D, Cho YY, Lau AT, et al (2008). Cyclin-dependent kinase 3-mediated activating transcription factor 1 phosphorylation enhances cell transformation. Cancer Res, 68, 7650-60.   DOI